Prostate Cancer

Encouraging Clinical Results From CG7870 Phase I/II Trial

Published in Gene Therapy Weekly, November 22nd, 2001

Cell Genesys, Inc., reported that a Phase I/II clinical trial of CG7870 (formerly CV787), an oncolytic virus engineered to target and destroy prostate cancer cells, demonstrated antitumor activity after only a single intravenous injection in patients with advanced hormone-refractory prostate cancer.

The Phase I/II trial was conducted at three medical centers under the direction of Eric Small, MD, clinical professor of medicine and urology at the University of California, San Francisco, Comprehensive Cancer Center. These data were reported at the European Cancer Conference (ECCO) being held in Lisbon, Portugal.

The Phase I/II study was a dose trial...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry